Mounjaro/Zepbound (tirzepatide), approved dual GLP-1/GIP agonist for type 2 diabetes and obesity Recent Highlights: In April 2026, the FDA approved orforglipron (Foundayo), making it one of the first oral GLP-1 pills that can be taken any time of day and that has no food or water restrictions
While the preclinical safety profile appears favorable (few adverse effects reported in animal studies), this does not guarantee the same in humans, especially with prolonged use
But, if you could say your name, your organization, and what you support or don't support, but we do understand the terrible impacts
Cleavage of Fusion Tags from Target Proteins A linker sequence is often incorporated between the target protein (POI) and tag sequence and, in many cases, designed to be cleaved to generate tag-free proteins of interest